These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21663844)

  • 1. Growth hormone and HIV infection: contribution to disease manifestations and clinical implications.
    Falutz J
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):517-29. PubMed ID: 21663844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment.
    Gelato M; McNurlan M; Freedland E
    Clin Ther; 2007 Nov; 29(11):2269-88. PubMed ID: 18158071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human growth hormone therapy in HIV-associated wasting and visceral adiposity.
    Yin MT; Glesby MJ
    Expert Rev Anti Infect Ther; 2005 Oct; 3(5):727-38. PubMed ID: 16207164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone-releasing factor agonists for the treatment of HIV-associated lipodystrophy.
    Hu M; Tomlinson B
    Curr Opin Investig Drugs; 2010 Oct; 11(10):1143-50. PubMed ID: 20872317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and management of body morphology changes and lipid abnormalities associated with HIV Infection and its therapies.
    Wohl DA
    Top HIV Med; 2004; 12(3):89-93. PubMed ID: 15310940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The use of growth hormone to treat endocrine-metabolic disturbances in acquired immunodeficiency syndrome (AIDS) patients].
    Spinola-Castro AM; Siviero-Miachon AA; da Silva MT; Guerra-Junior G
    Arq Bras Endocrinol Metabol; 2008 Jul; 52(5):818-32. PubMed ID: 18797589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wasting and lipodystrophy in patients infected with HIV: a practical approach in clinical practice.
    Fisher K
    AIDS Read; 2001 Mar; 11(3):132-3, 137-40, 147. PubMed ID: 17004351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The next generation of human growth hormone. How Serostim and tesamorelin measure up.
    Grodeck B
    Posit Aware; 2008; 19(5):28-32. PubMed ID: 18828236
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of androgens in patients who have HIV/AIDS: what we know about the effect of androgens on wasting and lipodystrophy.
    Abrams D
    AIDS Read; 2001 Mar; 11(3):149-56. PubMed ID: 17004352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV infection, body composition changes and related metabolic complications: contributing factors and evolving management strategies.
    Falutz J
    Curr Opin Clin Nutr Metab Care; 2011 May; 14(3):255-60. PubMed ID: 21460720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic therapy for HIV-associated lipodystrophy.
    Benavides S; Nahata MC
    Ann Pharmacother; 2004 Mar; 38(3):448-57. PubMed ID: 14755064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tesamorelin: a novel therapeutic option for HIV/HAART-associated increased visceral adipose tissue.
    Falutz J
    Drugs Today (Barc); 2011 Jun; 47(6):419-30. PubMed ID: 21695284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophy.
    Bickel M; Zangos S; Lutz T; Eisen J; Knecht G; Goebel FD; Crespi CM; Jacobi V; Staszewski S; Klauke S
    Scand J Infect Dis; 2008; 40(1):36-9. PubMed ID: 17852925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone deficiency in HIV-infected children following successful treatment with highly active antiretroviral therapy.
    Watson DC; Counts DR
    J Pediatr; 2004 Oct; 145(4):549-51. PubMed ID: 15480383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.
    Tomlinson B
    Curr Opin Investig Drugs; 2006 Oct; 7(10):936-45. PubMed ID: 17086939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of fat accumulation in patients with HIV infection.
    Falutz J
    Curr HIV/AIDS Rep; 2011 Sep; 8(3):200-8. PubMed ID: 21739217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity.
    ter Hofstede HJ; Burger DM; Koopmans PP
    Neth J Med; 2003 Dec; 61(12):393-403. PubMed ID: 15025414
    [No Abstract]   [Full Text] [Related]  

  • 19. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.
    Fantoni M; Del Borgo C; Autore C; Barbaro G
    Ital Heart J; 2002 May; 3(5):294-9. PubMed ID: 12066561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of recombinant human growth hormone in HIV-associated lipodystrophy.
    Burgess E; Wanke C
    Curr Opin Infect Dis; 2005 Feb; 18(1):17-24. PubMed ID: 15647695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.